Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Shuttle Pharmaceuticals Holdings, Inc. Common Stock

SHPH

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Last trade $3.91
Day change -$0.33 (-7.78%)
Day range $3.68 – $4.38
Volume 29,925
Market cap $20M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$20.2M
Price / earnings
—
Price / book
1.05×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.3×

Profitability

Earnings per share
-$2.15
Return on assets
-44.98%
Return on equity
-53.49%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.11×
Quick ratio
0.11×
Cash ratio
0.03×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SHPH, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.98M$1.16M$1.84M$886.06K$2.35M$596.89K$429.07K$329K
Research and development$55.66K$267.24K$511.88K$943.48K$1.03M$1.57M$986.41K$1.4M
Total operating expenses$3.95M$2.22M$2.79M$2.27M$3.91M$2.95M$1.78M$3.05M
Operating income-$3.95M-$2.22M-$2.79M-$2.27M-$3.91M-$2.95M-$1.78M-$3.05M
Interest expense$0-$12.12K-$18.25K-$18.9K-$21.74K-$11.93K-$159.28K-$272.68K
Income before taxes-$3.15M-$2.15M-$2.61M-$2.35M-$3.71M-$3.05M-$1.6M-$3.78M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.15M-$2.15M-$2.61M-$2.35M-$3.71M-$3.05M-$1.6M-$3.78M
Net income attributable to common shareholders-$3.15M-$2.15M-$2.61M-$2.35M-$3.71M-$3.05M-$1.6M-$3.78M
EBITDA-$1.41M-$794.46K-$2.07M-$1.83M-$3.37M-$2.17M-$1.41M-$1.73M
Basic earnings per share-$3.10-$4.30-$9.37-$10.50-$32.91-$76.00-$81.14-$398.30
Diluted earnings per share-$3.10-$4.30-$9.37-$10.50-$32.91-$76.00-$88.50-$398.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

E.F. Hutton & Co. announced it served as exclusive M&A advisor and placement agent for Shuttle Pharmaceuticals Holdings' acquisition of United Dogecoin Inc., creating one of the largest publicly traded Dogecoin mining platforms. The transaction included a $9.6 million PIPE financing to support mining operations expansion with next-generation equipment.

Benzinga

Shuttle Executes LOI with Molecule.ai

Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven drug discovery platform, for $10 million. The acquisition aims to leverage advanced machine learning models to accelerate pharmaceutical research and development.

GlobeNewswire Inc.

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals has successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma, a deadly brain cancer. The company has also finalized agreements with six clinical trial sites and raised additional funding to support the trial.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 11, 20261-for-10reverse split
Jun 16, 20251-for-25reverse split
Aug 13, 20241-for-8reverse split